Cordex Biologics Inc.
  • About us
  • Our Product
  • Science
  • Clinical Trials
  • News
  • Contact
  • English
    • Français
    • English
Select Page

ExCellThera Announces International Non-proprietary Name and New Orphan Drug Designation for UM171 Cell Therapy

by admin | Jun 4, 2024 | English

– UM171 Cell Therapy has been granted an International Nonproprietary Name (INN) of “dorocubicel” on the INN Recommended List issued by the World Health Organization (WHO) – The U.S. Food and Drug Administration (FDA) has granted UM171 Cell Therapy...

Recent Posts

  • Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells
  • Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells
  • ExCellThera Announces International Non-proprietary Name and New Orphan Drug Designation for UM171 Cell Therapy
  • ExCellThera announces new UM171 data to be presented at ASH 2023
  • UM171-Expanded Cell Therapy improves outcomes compared with other graft sources: Real-world evidence

Recent Comments

No comments to show.

Archives

  • August 2025
  • June 2025
  • June 2024
  • November 2023
  • August 2023

Categories

  • English